STOCK TITAN
  1. Home
  2. Sec-filings
  3. HURN
  4. [8-K] Huron Consulting Group Inc. Reports Material Event

Huron Consulting (NASDAQ: HURN) appoints Dr. L. Thomas Richards to board and committees

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Huron Consulting Group Inc. elected Dr. L. Thomas Richards to its Board of Directors, effective July 23, 2026, to serve until the 2027 Annual Meeting of Stockholders. He was also appointed to the Nominating and Corporate Governance, Finance and Capital Allocation, and Technology and Information Security committees.

As a non-employee director, Dr. Richards will receive an annual cash retainer of $80,000, plus $7,500 per year for each of the three committees and an annual restricted stock grant valued at $180,000. Because he joined within six months after the annual meeting, his initial cash retainer and 2026 restricted stock grant will be prorated, with the grant made on August 1, 2026 and vesting on its first anniversary. The company states there are no arrangements or understandings underlying his election and no transactions requiring disclosure under Item 404(a).

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Annual director cash retainer $80,000 Annual cash retainer for non-employee directors
Committee annual retainer $7,500 Annual retainer for each of the three Board committees
Annual restricted stock grant value $180,000 Value of annual restricted stock grant on the date of the annual meeting
Director appointment date July 23, 2026 Effective date of Dr. Richards’s election to the Board
Restricted stock grant date August 1, 2026 Date of Dr. Richards’s prorated initial restricted stock grant
Director term 2027 Annual Meeting Dr. Richards will serve until the 2027 Annual Meeting of Stockholders
Nominating and Corporate Governance Committee financial
"appointed to the Company’s Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Finance and Capital Allocation Committee financial
"appointed to the Company’s Finance and Capital Allocation Committee"
Technology and Information Security Committee financial
"appointed to the Company’s Technology and Information Security Committee"
restricted stock financial
"an annual grant of restricted stock on the date of the Company’s annual meeting"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
non-employee director compensation financial
"compensation in accordance with the Company’s non-employee director compensation practices"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What board change did Huron Consulting Group (HURN) disclose regarding Dr. L. Thomas Richards?
Huron Consulting Group elected Dr. L. Thomas Richards to its Board of Directors, effective July 23, 2026. He will serve until the 2027 Annual Meeting of Stockholders and has been appointed to three key board committees covering governance, finance and capital allocation, and technology and information security.

Which committees will Dr. L. Thomas Richards serve on at Huron Consulting Group (HURN)?
Dr. L. Thomas Richards joined Huron’s Board and its Nominating and Corporate Governance Committee, Finance and Capital Allocation Committee, and Technology and Information Security Committee. These assignments were effective July 23, 2026, aligning his responsibilities with governance, capital deployment, and technology and cybersecurity oversight.

How will Dr. L. Thomas Richards be compensated as a director of Huron Consulting Group (HURN)?
As a non-employee director, Dr. Richards will receive an $80,000 annual cash retainer, plus $7,500 annually for each of three committees and an annual restricted stock grant valued at $180,000. His initial cash retainer and 2026 equity grant will be prorated because of his mid-cycle appointment.

When will Dr. L. Thomas Richards’s restricted stock grant at Huron (HURN) be made and vest?
Because he joined shortly after the annual meeting, Dr. Richards will receive half of the annual restricted stock grant on August 1, 2026. This prorated grant will vest fully on the first anniversary of the grant date, subject to standard director terms.

What is the professional background of Dr. L. Thomas Richards joining Huron’s (HURN) board?
Dr. Richards previously served as Chair of WittKieffer’s board and held leadership roles at life sciences firms including One BioMed and TessArae. He is a board-certified emergency physician with an M.D. from Harvard Medical School and prior experience in M&A investment banking.
0001289848false00012898482026-07-232026-07-23


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 23, 2026
Date of Report (Date of earliest event reported)
_____________________
Huron Consulting Group Inc.
(Exact name of registrant as specified in its charter)
Delaware000-5097601-0666114
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification Number)
550 West Van Buren Street
Chicago, Illinois
60607
(Address of principal executive offices)
(Zip Code)
(312) 583-8700
(Registrant’s telephone number, including area code)
_____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.01 per shareHURNNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On and effective July 23, 2026, the Board of Directors (the “Board”) of Huron Consulting Group Inc. (“Huron” or the “Company”) elected Dr. L. Thomas Richards as a director of Huron, to serve until the 2027 Annual Meeting of Stockholders of Huron (the “2027 Annual Meeting”). Dr. Richards has been appointed to the Company’s Nominating and Corporate Governance Committee, Finance and Capital Allocation Committee and Technology and Information Security Committee, effective July 23, 2026. Dr. Richards will stand for re-election at the 2027 Annual Meeting.
Dr. Richards most recently served as Chair of the Board of Directors of WittKieffer, an executive search and leadership advisory professional services firm serving the healthcare, higher education and life sciences sectors. He has also served in a variety of roles across the life sciences industry with a focus on emerging technologies and innovation-driven growth, including as Interim Chief Executive Officer of One BioMed, a molecular tools company and Chief Executive Officer of TessArae, a molecular diagnostics company. In addition, he recently served as a Senior Advisor to Metis Genetics, a technology-enabled genetic counseling company, One BioMed, and Nanomix, a point-of-care diagnostic testing company, and advises venture capital and private equity investors across the life sciences industry. Dr. Richards also practiced academic medicine as an emergency physician and assistant professor at Stanford University and the University of California, San Francisco.
Earlier in his career, he was an investment banker in the mergers and acquisitions (M&A) groups of Lazard Frères, UBS and SG Cowen. Dr. Richards previously served on the board of directors of Cowen Group, Inc., a publicly traded financial services firm, and has served as a director of TessArae and One BioMed. He also currently serves on the boards of two non-profit organizations, The World Telehealth Initiative and the Surfrider Foundation. Dr. Richards received an M.D. from Harvard Medical School, an M.Phil. from the University of Sydney, and a B.A. from Yale University. He is a board-certified physician in Emergency Medicine.
As a director of Huron, Dr. Richards will receive compensation in accordance with the Company’s non-employee director compensation practices described in the Company’s 2026 Annual Proxy Statement filed with the Securities and Exchange Commission on March 20, 2026. This compensation generally consists of an annual cash retainer in the amount of $80,000, an annual retainer of $7,500 for service on the Nominating and Corporate Governance Committee of the Board, an annual retainer of $7,500 for service on the Finance and Capital Allocation Committee of the Board, an annual retainer of $7,500 for service on the Technology and Information Security Committee of the Board, and an annual grant of restricted stock on the date of the Company’s annual meeting with a value of $180,000. Because Dr. Richards joined the Company within the six months following the Company’s annual meeting, Dr. Richards's annual grant of restricted stock will be prorated such that Dr. Richards will receive half of the annual grant, which will be granted on August 1, 2026, and will vest fully on the first anniversary of the grant. Dr. Richards’s initial cash retainer will also be prorated to reflect his appointment date.
There are no arrangements or understandings between Dr. Richards and any other persons pursuant to which he was elected as a director. Dr. Richards has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.






SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Huron Consulting Group Inc.
(Registrant)
Date:July 27, 2026/s/    JOHN D. KELLY
John D. Kelly
Executive Vice President, Chief Financial Officer and Treasurer


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents